Embed Size (px)
Citation preview
Valvular Heart Disease
Ihab Alomari, MD, FACC Assistant Professor of Medicine Associate Director, Interventional Cardiology Fellowship Division of Cardiovascular Diseases University of California -Irvine
2
Disclosure
Nothing to disclose
Department Name | Month X, 201X
3
Background
Cardiology, 01, 2019
4
5
6
Dismal Outcomes of Severe Inoperable AS
7
8
9 Department Name | Month X, 201X
10
11
12
13
14
15
16
17
18
19
20
How it looks post-intervention
21
Core Valve system
22
Core Valve Specifics
Nitinol self expanding frame • One frame with three different diameters and radial/hoop
strengths. Porcine Pericardial Tissue • Leaflets and skirt elements
– Fixation and sterilization • Valve 26 mm, 29 mm, 31 mm • Partially repositionable
Study started in the U.S. in 2010.
23
How CoreValve looks post-intervention
24
25
26
PARTNER Inclusion Criteria
Severe AS: Echo-derived AVA < 0.8 cm2 (or AVA index < 0.5 cm2/m2) and mean AVG > 40 mm Hg or peak jet velocity > 4.0 m/s
Cardiac Symptoms: NYHA Functional Class ≥ II
High surgical risk: Predicted risk of operative mortality ≥ 15% (determined by site surgeon and cardiologist); STS score ≥ 10
Inoperable patients: Predicted risk of 30 day mortality ≥ 50% post-surgery or a serious irreversible condition. • ≥ 2 surgeons agreement that patient is inoperable.
27
Cohort B (inoperable)
28
Cohort B (inoperable)
29
Cohort B (inoperable)
30
Cohort B (inoperable)
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 Department Name | Month X, 201X
50
Mitral Clip
51
52 Department Name | Month X, 201X
53
Mitral Clip
54
55
56
57
58
59
60
61
62
63
64
What is Next ??
65
66
67
68
69
70
71
72
Thank you
Department Name | Month X, 201X
